Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Halozyme Therapeutics
Halozyme Therapeutics
Biopharma takeout spend ticks up
EP Vantage
Tue, 07/5/22 - 11:02 am
M&A
biotech
Pfizer
Biohaven
Bristol Myers Squibb
Turning Point Therapeutics
GSK
Affinivax
Sierra Oncology
Halozyme Therapeutics
Antares Pharma
Takeover-driven resurgence fails to materialize for biotech
EP Vantage
Thu, 04/14/22 - 10:41 am
M&A
AbbVie
Biocon
Biogen
Biohaven
GSK
Halozyme Therapeutics
Samsung Bioepis
UCB
Viatris
Halozyme Picks Up Antares' Drug Delivery Tech for Nearly $1B
BioSpace
Wed, 04/13/22 - 10:53 am
Halozyme Therapeutics
Antares Pharma
M&A
drug delivery
Medtech
GSK's ViiV, under threat from Gilead-Merck collab, eyes 'ultra-long-acting' HIV drugs with Halozyme deal
Fierce Pharma
Tue, 06/22/21 - 10:47 pm
GSK
ViiV Healthcare
Halozyme Therapeutics
Enhanze
HIV
drug delivery
Can Halozyme Therapeutics Continue Its Momentum in 2020?
Motley Fool
Mon, 03/2/20 - 11:10 pm
Halozyme Therapeutics
Enhanze
Halozyme to Restructure After Pancreatic Cancer Drug Fails in Phase 3; 55% of Workforce to be Cut
Xconomy
Mon, 11/4/19 - 10:42 am
Halozyme Therapeutics
pancreatic cancer
clinical trials
restructuring
layoffs
PEGPH20
Argenx and Halozyme Ink Multiple Target Deal That Could Hit $540 Million
BioSpace
Mon, 02/4/19 - 11:33 am
Argenx
Halozyme Therapeutics
drug delivery
drug development
3 Drug Stocks Hitting 52-Week Highs
Motley Fool
Tue, 10/17/17 - 09:42 am
Biogen
Halozyme Therapeutics
Ionis Pharmaceuticals
1 Great Biotech Stock You Have Never Heard Of
Motley Fool
Sun, 10/1/17 - 09:59 am
Halozyme Therapeutics
Roche
JNJ
Eli Lilly
Bristol-Myers Squibb